Article
Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia.
Biochemical pharmacology - 1 Dec 2023
Han Han, Zhao Chen, Liu Mengchen, Zhu Hongxuan, Meng Fancheng, Zhang Ying, Wang Guibin, Wang Li, Di Lijun, Mingyuen Lee Simon, Zhang Qingwen, Cui Guozhen
Abstract excerpt
Chronic myeloid leukemia (CML) is a hematologic malignancy predominantly driven by the BCR-ABL fusion gene. One of the significant challenges in treating CML lies in the emergence of resistance to tyrosine kinase inhibitors (TKIs), especially those associated with the T315I mutation. Homoharringtonine (HHT) is an FDA-approved, naturally-derived drug with known anti-leukemic properties, but its precise mechanisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.